Epigenetic sperm-function testing beyond count and motility — early, but a different diagnostic signal.

Inherent Biosciences

venture active confidence: Medium status: Draft updated 2026-07-14

Type: venture
Status: Draft
Confidence: Medium
Tier: C
Builder-tier: A
Activity-signal: 2026-01-26 · https://link.springer.com/article/10.1007/s10815-025-03791-0
Activity-checked: 2026-08-14
Focus: epigenetic diagnostics, male fertility, sperm function, reproductive health, AI biomarkers
Identifiers: cik=0001977505, ein=83-4457901
Roles: data-science, biology-life-sciences, clinical-regulatory
Stage: Private; Series A; NIH grant-funded
Primary Location: Salt Lake City, UT
Utah Location: Salt Lake City, UT
Region: Salt Lake City
Map Location: 26 S Rio Grande St, Suite 2072, Salt Lake City, UT 84101
Coordinates: 40.7687816, -111.9044144
Location Precision: exact
Location Source: https://www.inherentbio.com/contact-us
Website: https://www.inherentbio.com
Updated: 2026-07-14
Needs-reviewed: 2026-06-19
Relates: cites Official Website: Inherent Biosciences · https://www.inherentbio.com

Summary

Inherent Biosciences develops epigenetic tests that measure cell function, beginning with SpermQT for male infertility. Better diagnosis could shorten time to pregnancy and avoid unnecessary procedures at meaningful scale, but fertility testing is a bounded niche with substitutes.

Impact

Roughly half of infertile couples receive no male-factor explanation from count-and-motility testing even when sperm function is impaired. If epigenetic sperm-function assays improve diagnostic yield and treatment planning, they could shorten time-to-pregnancy and reduce unnecessary procedures — a meaningful but niche clinical impact.

Broader epigenetic-diagnostic impact is speculative: the science is plausible, but epigenetics-based tools have a mixed translation history and require rigorous population validation.

What They Are Building

Inherent uses AI to identify epigenetic patterns in sperm correlated with fertility outcomes. Path Fertility markets SpermQT to clinicians and couples as a higher-signal alternative to traditional semen analysis. The official website frames additional focus areas — sperm age, embryo quality, azoospermia, reproductive cancers — as future or parallel applications.

What They Need Now

Likely needs include epigenomics scientists, bioinformaticians, clinical-laboratory operators, reproductive endocrinology KOLs, and reimbursement strategists. Small-team contributors can have high leverage; regulatory and CLIA/LDT pathways for diagnostic products are core constraints.

Who Could Help

Useful helpers include fertility-clinic distribution partners, NIH grant administrators, reproductive-health payers and reimbursement advisors, and Utah life-sciences ecosystem connectors (Nucleus Utah and related networks).

Utah Context

Inherent publishes a Salt Lake City office on the Wasatch Front, part of Utah's growing diagnostics and digital-health cluster alongside companies like Techcyte and Owlet Baby Care.

Evidence

Open Questions

Careers URL: No agent-readable careers board found (2026-07-14). inherentbio.com/careers 404; site warns against work-from-home hiring scams but does not list openings.
What are SpermQT's validated sensitivity, specificity, and clinical outcomes versus standard semen analysis?
Reimbursement and payer coverage status for epigenetic fertility testing?
Can the epigenetic platform generalize beyond fertility to autoimmune, developmental, or aging indications — and on what timeline?
Epigenetic diagnostics are noisy; what controls reproducibility across labs and populations?